Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma

Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) presents a formidable challenge with high lethality and limited effective drug treatments. Its heightened metastatic potential further complicates the prognosis. Owing to the significant toxicity of current chemotherapeutics, compounds like [Met<sup>5<...

Full description

Bibliographic Details
Main Authors: Justyna Budka, Dawid Debowski, Shaoshan Mai, Magdalena Narajczyk, Stanislaw Hac, Krzysztof Rolka, Eirinaios I. Vrettos, Andreas G. Tzakos, Iwona Inkielewicz-Stepniak
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Pharmaceutics
Subjects:
opioid growth factor
[Met<sup>5</sup>]-enkephalin
gemcitabine
peptide-drug conjugates
pancreatic cancer
pancreatic cancer organoids
Online Access:https://www.mdpi.com/1999-4923/16/2/283

Internet

https://www.mdpi.com/1999-4923/16/2/283

Similar Items